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The role of the Escherichia coli iron-regulated gene homologue adhesin (Iha) in the pathogenesis of urinary
tract infections (UTIs) is unknown. We performed a series of complementary analyses to confirm or refute the
hypothesis that Iha is a virulence factor in uropathogenic E. coli. Fecal E. coli isolates exhibited significantly
lower prevalences of iha (range, 14 to 22%) than did clinical isolates from cases of pediatric cystitis or
pyelonephritis, adult pyelonephritis or urosepsis, or bacteremia (range, 38 to 74%). Recombinant Iha from E.
coli pyelonephritis isolate CFT073 conferred upon nonadherent E. coliORN172 the ability to adhere to cultured
T-24 human uroepithelial cells. In a well-established mouse model of ascending UTI, CFT073 and its derivative
UPEC76 (a pap [P fimbriae] mutant version of strain CFT073) each significantly outcompeted their respective
iha deletion mutants in CBA/J mice 48 h after bladder challenge (P < 0.03 for urine, both kidneys, and
bladders of both constructs, except for bladders of mice challenged with UPEC76 and its deletion mutant,
where P  0.11). These data suggest that IhaCFT073 is a virulence factor and might be a target for anti-UTI
interventions.
Extraintestinal pathogenic Escherichia coli cells produce di-
verse factors (6, 13, 16) that allow them to overcome or subvert
host defenses and to colonize, injure, and invade host cells or
tissues. Delineation of the roles of these factors could lead to
measures to prevent or attenuate infections caused by the
organisms that express them (28, 29).
iha encodes the IrgA homologue adhesin (Iha), an outer
membrane protein (OMP) first characterized in E. coli O157:
H7, which confers adherence to nonadherent laboratory
strains (41). iha occurs frequently among uropathogenic E. coli
strains (3, 16–18, 22, 23, 25, 27). Its designation is derived from
the similarity of Iha to IrgA (9), which is postulated to play a
role in the colonization of mice experimentally infected with
Vibrio cholerae (10).
ihaO157:H7 and open reading frame R4 in pathogenicity-
associated island 1 (PAI-1) of the well-studied E. coli pyelo-
nephritogenic strain CFT073 (serotype O6:K2:H1) (12) differ
by five synonymous nucleotide changes and one nonsynony-
mous nucleotide change. Strain UPEC76, a derivative of
CFT073 in which both pyelonephritis-associated pap (pilus as-
sociated with pyelonephritis; P fimbriae) operons, in separate
PAIs, have been inactivated by deletions, colonizes the urinary
tract in a mouse model of ascending urinary tract infection
(UTI) as well as does its parent (32). This finding suggests that
CFT073 requires non-pap loci for virulence, with iha being one
such candidate critical locus. Also, the virulence of a Proteus
mirabilis strain, in which irgA was identified by signature-
tagged mutagenesis, was attenuated in a mouse model of as-
cending UTI (4).
Because Iha’s status as a virulence factor has been incom-
pletely elucidated, we performed complementary studies to
test the hypotheses that iha extraintestinal pathogenic E. coli
iha is epidemiologically associated with human disease, that
cloned iha confers the ability to adhere to uroepithelial cells,
and that IhaCFT073 is needed for complete urovirulence in mice
challenged with strain CFT073 or UPEC76.
MATERIALS AND METHODS
Bacteria and plasmids used. E. coli strains CFT073, UPEC76 (32), and 86-24
(serotype O157:H7) (41) have been previously described. Ampicillin and nalidixic
acid concentrations in media were 200 and 20 g ml1, respectively. Cloned PCR
products were transformed into E. coli strains DH5 (36) and ORN172, a laboratory
E. coli strain devoid of all known adherence mechanisms including type 1 pili (46).
Nalidixic acid-resistant CFT073 (CFT073nalR) was derived by plating ca. 1010
CFT073 cells on Luria-Bertani (LB) agar containing nalidixic acid and selecting a
spontaneously resistant mutant. E. coli SM10(pir) (38) was transformed with, and
then was the donor for, suicide plasmid constructs. E. coli strain B171 (O111:NM)
(33) was used as a positive adherence control. pSKIha-O157:H7, formerly pIha, is
pSK (Stratagene, La Jolla, Calif.) containing cloned ihaO157:H7 (41). To clone and
express IhaCFT073, we amplified CFT073 DNA with primers A (5GGGGATCCA
ATTCTGGCATGCCGAGGCAGTGC3) and B (5GGTCTAGATTCTCGTTG
CCACTGTTCCGCCAGG3) (41), containing engineered 5 BamHI and XbaI
sites, respectively. This amplicon, consisting of ihaCFT073 and 141 and 80 bp 5 and
3 to its termini, respectively, was digested with BamHI and XbaI and cloned into the
corresponding sites in pSK, resulting in pSKIha-CFT073. It was then sequenced
bidirectionally.
Deletion of ihaCFT073 from CFT073 and UPEC76. To create an in-frame,
unmarked, isogenic deletion of iha in strains CFT073 and UPEC76, we cloned an
in-frame deletion construct of the target gene into suicide plasmid pCVD442 (5).
We used inverse PCR (42) to obtain a candidate DNA sequence (not shown) 5
to ihaCFT073. We then used primer C (5GCAGAGCTCCCTTGCAAGAGGG
CGTCGAGC3) and 5GCTATGGATCCGGCTGAAAATCCGAGACAGGG3
to produce a 704-bp amplicon that includes the 5 terminus of ihaCFT073 and 630 bp
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of the 5 noncoding region. This amplicon was sequentially cloned into, and
excised from, the pGem-TEasy vector and pSK with SacI and BamHI. Next,
the cloned 558-bp amplicon that spans the ihaO157:H7 3 terminus (41), which
differs from the corresponding region in CFT073 by only 3 nucleotides in the
downstream noncoding region of the gene, was excised from pSK with BamHI
and XhoI and ligated to the SacI-BamHI fragment spanning the 5 ihaCFT073
terminus. This fusion, representing a central truncation of ihaCFT073, was then
cloned into and excised from the pSK SacI and XhoI sites and finally inserted
into the SacI and XhoI sites of pCVD442 (5), producing pCVD442ihaCFT073.
Though the 5 end of primer C imperfectly represents the iha upstream region,
the deletion mutant is, as intended, identical to its parent at that site (sequence
data not shown).
CFT073nalR or UPEC76 was mated separately with E. coli SM10(pir) trans-
formed with pCVD442ihaCFT073 on LB agar at 37°C. Transconjugants were
selected by plating mated bacteria on LB agar containing ampicillin and nalidixic
acid. The resulting presumed merodiploids were grown (37°C in LB broth [36]),
plated onto LB agar containing 5% sucrose but no NaCl, and incubated (30°C).
Sucrose-resistant, ampicillin-susceptible colonies from these matings were des-
ignated CFT073ihaCFT073 and UPEC76ihaCFT073, respectively.
Deletion mutant characterizations. Genomic DNA from the presumptive mu-
tants and their parents was digested with BstXI, electrophoresed, transferred to
a MagnaCharge nylon membrane (GE Osmonics, Minnetonka, Minn.), and
probed with ihaO157:H7. A 371-bp amplicon produced by primers A and B from
each candidate deletion mutant was cloned into pSK and sequenced. The
deletion mutants were serotyped by Flemming Scheutz, digested with XbaI, and
analyzed by pulsed-field gel electrophoresis, and tested by PCR for 11 (iha, papA,
papC, sfa/focDE, focG, fimH, iutA, fyuA, iroN, hlyD, and malX) (11, 26) putative
or demonstrated urovirulence loci that are known to be present in the parent
plus, specifically, the F7-1 and F7-2 papA alleles (21, 22). The deletion mutants
and their parents were also evaluated for mannose-sensitive agglutination of
guinea pig erythrocytes and baker’s yeast and for mannose-resistant agglutina-
tion of human erythrocytes after overnight growth in static broth or on agar
plates to indicate expression of type 1 or P fimbriae, respectively (24), and for
differences in growth rates (compared to parents) over 18 h in LB broth shaken
at 37°C. Finally, the mutants were hybridized with digoxigenin-labeled pCVD442
to confirm suicide plasmid loss.
Anti-Iha antibodies. The PolyQuik protocol (Zymed Laboratories, South San
Francisco, Calif.) and affinity purification produced lapine polyclonal antibodies
against an Iha epitope. The resulting affinity-purified antibodies (designated
anti-Iha antibodies) do not detect an externally directed Iha epitope (41).
OMP analyses. OMPs were prepared (1) from bacteria grown overnight at
37°C in 100 ml of LB broth or Dulbecco’s minimal essential medium (D-5030;
Sigma, St. Louis, Mo.) containing 0.45% glycerol, 25 mM HEPES, 10 mM
sodium pyruvate, 4.5 mN sodium hydroxide, 4 mM L-glutamine, and 44 mM
sodium bicarbonate (DMEM). Protein concentrations were determined (protein
assay kit; Bio-Rad, Hercules, Calif.). OMPs (2 g) in loading buffer were elec-
trophoretically separated (sodium dodecyl sulfate–10% polyacrylamide) and
transferred to membranes (Immobilon-P; Millipore, Billerica, Maine) or Coo-
massie stained to confirm equal loading of analyte. The membranes to which the
proteins were transferred were blocked overnight in antibody buffer (phosphate-
buffered saline with 0.05% [vol/vol] Tween 20) containing 5% nonfat dried milk
and 0.02% sodium azide) and washed once with antibody buffer. The membranes
were then incubated overnight with anti-Iha antibodies diluted 1:2,000 in anti-
body buffer, washed three times with antibody buffer, incubated for 30 min with
affinity-purified goat anti-rabbit immunoglobulin G (heavy plus light chains)
peroxidase conjugate (Boehringer Mannheim, Indianapolis, Ind.) diluted 1:2,000
in antibody buffer, and washed again three times with antibody buffer. Mem-
branes were incubated at 4°C or room temperature (blocking or all subsequent
steps, respectively). Bound antibodies were detected with the use of the Super-
Signal Western blotting (Pierce, Rockford, Ill.).
Adherence assay. T-24 human bladder epithelial cells (30), after growth to
confluence at 37°C in 5% CO2 in plastic flasks in culture medium (McCoy’s 5a
medium; Sigma; M-4892) supplemented with 10% (vol/vol) heat-inactivated fetal
bovine serum, were trypsinized, pelleted, resuspended in the above medium, and
then added to wells (in 2-ml volumes) of a six-well plastic flat-bottom cell culture
plate (Costar 3516; Corning, Corning, N.Y.) containing sterile plastic 25-mm-
diameter coverslips. When cells were ca. 75% confluent, the medium was re-
placed with fresh medium containing mannose (0.5%) and ampicillin, and ad-
herence assays were performed.
E. coli strain B171 and E. coli ORN172 containing pSKIha-CFT073 or pSK
were grown in LB broth with ampicillin at 37°C without shaking, before assess-
ment in the adherence assay. Cells and bacteria were incubated for 1 (wild type
and wild-type derivatives) or 2 h (ORN172 transformants) at 37°C in 5% CO2,
after which they were washed eight times with sterile phosphate-buffered saline,
fixed (100% methanol, 1 min), stained (0.5% crystal violet, 15 min), and thor-
oughly washed with water to remove background stain. Coverslips were then air
dried and mounted on glass slides, and adherent organisms were enumerated by
a microscopist unaware of the identity of the organisms in each well. The test
organisms were concurrently assessed in duplicate on each of multiple days. Five
fields were randomly selected for analysis from each of two duplicate wells per
test organism. The adherent organisms were counted separately for each cell
within each selected field.
Molecular epidemiological analyses. iha was sought in E. coli from the feces of
healthy volunteers and noninfected hospitalized subjects and from E. coli recov-
ered from the urine, blood, or cerebrospinal fluid of infected patients by PCR
with internal primers D (5CTGGCGGAGGCTCTGAGATCA3) and E (5TC
CTTAAGCTCCCGCGGCTGA3) and/or by dot blot hybridization with an in-
ternal digoxigenin-labeled iha probe (synthesized with primers D and E) (22).
Isolates were tested in duplicate, with independently prepared boiled lysates, for
the presence of iha. Strains CFT073 and K-12 were the positive and negative
controls, respectively (22, 25).
Mouse models of UTI. In an extensively evaluated ascending atraumatic model
of UTI, 6- to 10-week-old CBA/J mice were anesthetized and inoculated via the
urethra with 1.0 l of the test bacterial suspension/g of body weight1, under
conditions that avoided vesicoureteral reflux (14, 15, 35). Challenge bacteria
were grown in shaking, overnight LB broth cultures at 37°C, pelleted, and
resuspended in LB broth before challenge. After a standard 2-day period, mice
were euthanized, and aseptically harvested urine and bladder and kidney ho-
mogenates were cultured quantitatively on agar. Dual-strain challenges were
used to compare the colonizing abilities of CFT073 and of UPEC76 to those of
their respective iha deletion mutants. Intra-animal competition assessments were
used in these studies because they minimize the impact of mouse-to-mouse
variation and maximize the ability to identify differences among test strains. The
challenge inocula contained ca. 2  109 total CFU, which is standard in our use
of this model and which is within the range used by others (7, 32, 43) in various
mouse models of UTI.
Because we used unmarked mutations in competition experiments, neither
CFT073 nor UPEC76 could be easily phenotypically differentiated from their
respective ihaCFT073 mutants in the postmortem cultures in mouse UTI models.
Therefore, we tested colonies from each mouse culture, randomly selected to
preclude systematic bias favoring one test strain over the other, by using dot blot
hybridization with an internal iha probe or PCR with internal iha primers D and
E (25) to determine the relative proportions of recovered organisms that con-
tained an intact copy of iha. Each isolate was analyzed in duplicate, with the
corresponding challenge strains used as controls. Colonies from the inoculum
suspension cultures were similarly analyzed to define the relative abundances of
the two test strains as administered to the mice, and this proportion (the input
ratio) was used to adjust the postmortem quantitative culture results (the output
ratio) from the mouse infection experiments to obtain the competitive index
(CI). Between 10 and 64 colonies per culture (i.e., from inoculum suspensions
and postmortem samples) were so assessed. In addition, to exclude contamina-
tion, one putative representative of each test strain from each positive culture
from the mouse experiments was compared with the actual test strain by random
amplified polymorphic DNA analysis (22, 44).
Statistics. Differences in proportions were tested for significance by Fisher’s
exact test for unpaired comparisons or McNemar’s test for paired comparisons.
Differences involving continuous variables were assessed for significance by the
Mann-Whitney U test and the Wilcoxon rank sum tests for unpaired and paired
comparisons, respectively. The threshold for statistical significance was a P value
	0.05, but selected values 	0.10 are noted in Table 2 to demonstrate trends.
Nucleotide sequence accession number. The nucleotide sequence of the region
upstream of ihaCFT073 in CFT073 has been deposited in the GenBank database
under accession number AF401752.
RESULTS
Molecular epidemiology of iha. To determine the epidemi-
ological association of iha with specific extraintestinal infection
syndromes, iha was sought among 286 fecal E. coli isolates and
839 clinical isolates from diverse human populations (Table 1).
Fecal isolates consistently exhibited a lower prevalence of iha
(range, 14 to 22%) than did clinical isolates from all infection
syndromes except cystitis in women and neonatal meningitis.
The highest prevalences of iha (50 to 74%) occurred among
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cystitis and pyelonephritis isolates from children and pyelone-
phritis and urosepsis isolates from adults. Intermediate preva-
lences (38 to 39%) that still significantly exceeded control
frequencies were observed among bacteremia isolates from
diverse sources. These differences demonstrate that Iha fulfills
the first of the molecular restatement of Koch’s postulates,
which requires that the property of interest be epidemiologi-
cally associated with disease (8).
Structure of ihaCFT073 and its upstream region. IhaCFT073
has a deduced molecular size of 78 kDa and contains 696
amino acids. IhaCFT073 and IhaO157:H7 differ by only one amino
acid (an Asp4693Asn469 alteration), but the two iha genes
differ by 6 nucleotides. Upstream of the iha ATG start codon,
CFT073 and E. coli O157:H7 are 98.8 and 34.8% identical
from position 1 to 489 and positions 490 through 630,
respectively, consistent with CFT073’s extensive chromosomal
mosaicism (45).
Role of IhaCFT073 in adherence of E. coli to uroepithelial
cells. pSKIha-CFT073 conferred on E. coli ORN172 the ability
to adhere to cultured T-24 uroepithelial cells, whereas pSK
did not (Fig. 1). The adherence pattern observed for E. coli
ORN172 transformed with pSKIha-CFT073 was diffuse, and
there was interfield variability. This adherence pattern of Iha
recombinants was also observed on HEp-2 cells (data not
shown). Strain B171 displayed its characteristic localized ad-
herence to cells (data not shown). Assessments of the cellular
adherence of CFT073 or UPEC76, their iha deletion mutants,
or their deletion mutants transformed with pSKIha-CFT073
and pSK were precluded by the considerable cytotoxicity of
these strains (31), even after only 1 h of incubation (data not
shown).
Comparisons of CFT073 to CFT073ihaCFT073, and of
UPEC76 to UPEC76ihaCFT073. Compared with their respec-
tive parents, CFT073ihaCFT073 and UPEC76ihaCFT073 ex-
hibit the same growth characteristics, colony morphology,
O:K:H serotype, XbaI pulsed-field gel electrophoresis profile,
baker’s yeast and erythrocyte agglutination patterns, and ex-
tended virulence genotype (except, of course, for ihaCFT073).
FIG. 1. Adherence of laboratory E. coli to T-84 uroepithelial cells, with and without cloned Iha. Shown is E. coli ORN172 transformed with
pSK (A) or pSKIha-CRT073 (B). Panel B demonstrates the typical adherence of E. coli ORN172 transformed with pSKIha-CFT073 to cells, but
the adherence intensity is variable, with some cells quite densely covered (B, inset). Numbers are values associated with cellular adherence for the
corresponding recombinant strains. The P value in panel B is relative to the vector control (Mann-Whitney U test). Bars, 20 m.
TABLE 1. Prevalence of iha among fecal and clinical isolates of E. coli from diverse host populations
Group
no.




P: (by Fisher’s exact test) for comparison with group no.: Referenceb for:
1 2 3 4 5 6 7 8 9 10 11 12 13 Isolates iha data
1 Healthy women (fecal) 13/77 (17)
2 Healthy children (fecal) 9/46 (20) —
3 Healthy adults (fecal) 20/92 (22) — —
4 Hospitalized veterans (fecal) 10/71 (14) — — — 36a 36a
5 Pediatric cystitis 26/39 (74)     19
6 Pediatric cystitis 22/44 (50)     — 2
7 Pediatric pyelonephritis 25/48 (52)     — — 2
8 Women, cystitis 12/74 (16) — — — —    22 22
9 Women, cystitis 22/82 (27) — — — —    —
10 Women, pyelonephritis 97/170 (57)     — — —   42
11 Adults, urosepsis 37/66 (56)     — — —   — 26 26
12 Adults, bacteremia 69/182 (38)      — —  —   36a 36a
13 Veterans, bacteremia 25/64 (39)      — —  —  — —
14 Neonatal meningitis 13/70 (19) — — — —    — —     24a 24a
a P value symbols: —, P 
 0.05; , P  0.05; , P  0.01; , P  0.001.
b If sources for these collections were not this study.
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By Southern hybridization, 4.7-kb BstXI fragments detected by
the iha probe in CFT073 and UPEC76 were not evident in
their respective ihaCFT073 mutants. Most importantly, sequenc-
ing across the target deletion site demonstrated a 1,939-bp
deletion in CFT073ihaCFT073 and UPEC76ihaCFT073, with the
intended insertion of GATC. This resulted in the in-frame
replacement of the 647 amino acids between Glu25 and Gln673
with a Gly and a Ser.
OMP analysis. Anti-Iha antibodies detected abundant 76-
kDa antigen, as well as probable breakdown products, in OMPs
from E. coli ORN172 transformed with pSKIha-O157:H7 or
pSKIha-CFT073 (Fig. 2A). OMPs from strains CFT073 and
UPEC76 produced less intensely immunoreactive 76-kDa Iha
(Fig. 2A). As expected, OMPs from iha deletion mutants
UPEC76ihaCFT073 and CFT073ihaCFT073 did not exhibit Iha
antigen (Fig. 2B and C). Iha was not detectable when CFT073
was grown in LB broth but was detectable when it was grown in
DMEM (Fig. 2D).
In vivo challenge experiments. CBA/J mice were challenged
via the urethra with mixtures of CFT073 and CFT073ihaCFT073
or mixtures of UPEC76 and UPEC76ihaCFT073, in dual-strain
competition model experiments. Urine, bladders, and kidneys
harvested 48 h after inoculation uniformly showed greater overall
intensity and prevalence of colonization with CFT073 or UPEC76
than with these strains’ respective ihaCFT073 mutants, as sum-
marized for categorical outcomes in Table 2 and as illustrated for
absolute log10 CI values in Fig. 3. Of note, many cultures yielded
only the parent strain, indicating that the mutants were present at
levels below the detection threshold or were lost in vivo. These
data establish the contribution of ihaCFT073 to bladder and kidney
colonization in mice challenged with a urovirulent E. coli strain,
with or without an intact pap operon.
DISCUSSION
The impaired abilities to colonize the mouse urinary tract
displayed by isogenic, in-frame, ihaCFT073 deletion mutants in
two different E. coli backgrounds provide strong experimental
support for the hypothesis that Iha is a urovirulence factor.
That IhaCFT073 conferred the ability to adhere to T-24 cells is
particularly interesting, because E. coli adherence to these cells
of human bladder origin has been reported to be independent
of known UTI-associated adhesins, such as type 1, P, or S
fimbriae, or afimbrial adhesin I (30). These assay results also
demonstrate that the single amino acid difference between
IhaCFT073 and IhaO157:H7 does not negate the ability of the
cloned protein to confer cellular adherence capability to non-
adherent laboratory E. coli. This phenotype, though antici-
pated, warranted confirmation because of the known ability of
single amino acid polymorphisms to alter the receptor binding
characteristics of the pathogenetically important E. coli adhe-
sin, FimH (39). Whether Iha augments adherence directly or
indirectly via effects on other bacterial components and, if it
acts directly, whether this phenotype involves receptor-specific
or nonspecific binding to the host cell await further assessment.
FIG. 2. OMPs of E. coli ORN172, with and without recombinant
IhaCFT073, and wild-type and derivative E. coli. (A) Immunoblots of
OMPs from strain ORN172 transformed with pSK (lane 1),
pSKIha-O157:H7 (lane 2), pSKIha-CFT073 (lane 3), E. coli CFT073
(lane 4), UPEC76 (lane 5), and E. coli O157:H7 (lane 6). (B to D)
Immunoblots of OMPs from CFT073 (B, lane 1), CFT073iha-CFT073
(B, lane 2), UPEC76 (C, lane 1), UPEC76iha-CFT073 (B, lane 2),
UPEC76 (C, lane 1), UPEC76iha-CFT073 (C, lane 2), and CFT073
grown in LB broth (D, lane 2) or DMEM (D, lane 2). The single
immunoreactive bands in panels B to D represent the 76-kDa Iha
antigen.
TABLE 2. Comparative urovirulences of CFT073 and UPEC76 versus their respective ihaCFT073 derivatives in the mouse model of
ascending UTI (competition experiments)












Parent only ihaCFT073mutant only
CFT073nalR Urine 19 12 (63) 2 (11) 	0.02 8 (42) 0 (0) 	0.01
Bladder 19 16 (84) 3 (16) 	0.01 2 (11) 0 (0)
Right kidney 19 11 (58) 1 (5) 	0.01 2 (11) 0 (0)
Left kidney 19 11 (58) 1 (5) 	0.01 4 (21) 0 (0)
UPEC76 Urine 24c 17 (71) 5 (21) 0.017 7 (29) 1 (4) 0.07
Bladder 30 18 (60) 11 (37) 6 (20) 0 (0) 0.03
Right kidney 30 19 (63) 7 (23) 0.03 8 (27) 3 (10)
Left kidney 30 16 (53) 8 (27) 9 (30) 5 (17)
a Percentages do not sum to 100% in all instances because some cultures (included in denominators) yielded no growth. Comparative prevalence of the competing
strains was assessed based on the CI, i.e., after adjusting the output ratio from that culture for the input ratio from the same experiment.
b Percentages do not sum to 100% because some cultures yielded no growth or growth of both competing strains.
c Urine was unavailable for six mice from the UPEC76 experiments.
d P values (by McNemar’s test; two tailed) are provided where P 	 0.10.
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Additionally, our work confirms the localization of Iha to the
cell envelope of another iha strain and demonstrates that its
presence in the cell envelope of CFT073, like the presence of
the Iha homologue in the cell envelope of locus of enterocyte
effacement-negative E. coli O91:H strain 4797/97 (37), de-
pends on the growth medium of the organism, with expression
being suppressed in LB broth. Indeed, this diminished expres-
sion in LB broth might have actually led to an underattribution
of the role of Iha in the mouse colonization experiments,
because the challenge inocula were prepared in LB broth,
which would tend to diminish the expression of Iha in the
parent at the time of inoculation.
The mutations that produced the colonization deficiencies of
CFT073 and UPEC76 were each in-frame deletions of
ihaCFT073. Such deletions are quite unlikely to exert polar ef-
fects on downstream genes, although we cannot exclude com-
pletely the possibility that occult cis-acting effects of the dele-
tion reduced colonization ability. Additionally, the deletion
mutants were indistinguishable from the parent with respect to
a broad panel of characteristics analyzed other than ihaCFT073
and antigenic IhaCFT073. Moreover, two independent deletions
of ihaCFT073 in two different organisms produced the same
diminished-colonization phenotype, to similar extents, without
perturbing other analyzed loci. Recent data demonstrate the
fairly frequent occurrence of secondary mutations in extrain-
testinal pathogenic E. coli using pCVD442 (20); therefore, it is
important to generate such confirmatory results to increase
confidence that the altered phenotype actually was caused by
the intended mutation. The extensive methods that we used to
exclude unanticipated secondary mutations in the iha mutants
exceed those customarily used for this purpose in studies of
this sort and were the same as those that uncovered otherwise-
occult secondary mutations in the recent study; their use in-
creases confidence that such alterations were absent from the
present mutants.
Although inactivating papG in E. coli pyelonephritis strain
DS17 (O6:K5) by introducing a premature stop codon reduced
the ability of this strain to cause ascending pyelonephritis in
monkeys (34), inactivation of both pap operons in CFT073 did
not diminish CFT073’s ability to colonize the mouse urinary
tract (32). Likewise, inactivating the putative virulence factor
sat (secreted autotransporter toxin) in CFT073 had no impact
on in vivo colonization ability (32). Thus, iha joins tonB, iutA,
chuA, and fimH as the only known putative urovirulence genes,
the mutation of which in the CFT073 background significantly
attenuates urovirulence (43). Moreover, ihaCFT073 is the first
such gene for which an unmarked, in-frame deletion was used
to generate the evaluated CFT073 mutant.
Finally, our epidemiological data provide novel molecular
evidence that iha is statistically significantly more frequent
among diverse groups of extraintestinal E. coli pathogens than
among fecal control isolates. The absence of a categorical
association of iha with all infection syndromes and host groups
suggests differing pathogenetic mechanisms across clinical and
epidemiological settings, a worthy topic for future investiga-
tions.
In summary, IhaCFT073’s demonstrated pathogenetic impor-
tance in a mouse model of UTI complements (i) epidemiolog-
ical data associating iha with recurrent or invasive UTI and
diverse-source bacteremia and (ii) in vitro uroepithelial adher-
ence data. However, even though ihaCFT073 mutants exhibited
impaired in vivo colonization in two different bacterial hosts
and although this colonization deficit is plausibly attributable
to iha’s adherence-conferring function, Iha CFT073 has not yet
been proven to serve as an adhesin in wild-type pathogens.
Nonetheless, our data suggest that Iha deserves further scru-
tiny as a molecule to exploit for prevention or treatment of
human UTIs.
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FIG. 3. Comparative urovirulences in mice of CFT073 and
UPEC76 versus those of their respective ihaCFT073 mutants. Mice
were challenged via the urethra with 20 l containing ca. 2  109 CFU
of a mixture of CFT073 and CFT073iha-CFT073 (A) or UPEC76 and
UPECihaCFT073 (B). CIs were calculated as the parent/deletion mu-
tant ratios, normalized to the corresponding input ratio. X, no growth;
horizontal bars, median values.
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